SCA
PEAR

Sandy Cove Advisors’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Sandy Cove Advisors’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$1K – 417
2022
Q1 		$1K Buy
+100
New +$454 ﹤0.01% 412

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sandy Cove Advisors's PEAR Position: Q2 2022 in Review

Sandy Cove Advisors sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2022, closing a stake of 100 shares — an estimated $1K sold.

Sandy Cove Advisors first reported a position in PEAR in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 40 funds tracked by Wall St. Rank hold PEAR as of Q2 2022.

  • Sandy Cove Advisors reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • Sandy Cove Advisors sold 100 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2022, an estimated $1K.
  • Sandy Cove Advisors first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 1 quarter.
  • Sandy Cove Advisors's Pear Therapeutics, Inc. Class A Common Stock position peaked at $1K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2022.

Based on Sandy Cove Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.